Hyperglycemia decreases anti-cancer efficiency of Adriamycin via AMPK pathway

Xiaqing Xu; Meimei Si; Honggang Lou; Youyou Yan; Yunxi Liu; Hong Zhu; Xiaoe Lou; Jian Ma; Difeng Zhu; Honghai Wu; Bo Yang; Haoshu Wu; Ling Ding; Qiaojun He

doi:10.1530/ERC-18-0036

Hyperglycemia decreases anti-cancer efficiency of Adriamycin via AMPK pathway

Endocr Relat Cancer. 2020 Feb 1;27(2):X3-X4. doi: 10.1530/ERC-18-0036.

Authors

Xiaqing Xu¹, Meimei Si¹, Honggang Lou², Youyou Yan¹, Yunxi Liu¹, Hong Zhu¹, Xiaoe Lou¹, Jian Ma¹, Difeng Zhu¹, Honghai Wu¹, Bo Yang¹, Haoshu Wu¹, Ling Ding¹, Qiaojun He¹

Affiliations

¹ Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, Institute of Pharmacology & Toxicology and Biochemical Pharmaceutics, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China
² Department of Clinical Pharmacology, The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China

PMID: 32022504
DOI: 10.1530/ERC-18-0036

Abstract

The authors and journal apologise for an error in the above paper, which appeared in volume 25 part 11, pages 955–966. The error relates to the artwork of Fig. 5 on page 963, in which the blots given in panel E were mistakenly replicated in panel F.

Publication types

Published Erratum